Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$36.72
-1.23-3.24%
At close: -
$36.73
0.010000.03%
After Hours: Jun 27, 5:51 PM EDT
Comments
Loading...
TG Therapeutics Analyst Ratings and Price Targets | NASDAQ:TGTX | Benzinga
TG Therapeutics Inc has a consensus price target of $33.22 based on the ratings of 10 analysts. The high is $55 issued by HC Wainwright & Co. on March 4, 2025. The low is $6 issued by B of A Securities on December 29, 2022. The 3 most-recent analyst ratings were released by HC Wainwright & Co., HC Wainwright & Co., and JP Morgan on March 4, 2025, January 15, 2025, and November 25, 2024, respectively. With an average price target of $51 between HC Wainwright & Co., HC Wainwright & Co., and JP Morgan, there's an implied 38.85% upside for TG Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
JP Morgan
Goldman Sachs
TD Cowen
B. Riley Securities
1calculated from analyst ratings
Analyst Ratings for TG Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 03/04/2025 | Buy Now | 49.74% | HC Wainwright & Co. | Edward White46% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 01/15/2025 | Buy Now | 49.74% | HC Wainwright & Co. | Edward White46% | $55 → $55 | Reiterates | Buy → Buy | Get Alert |
| 11/25/2024 | Buy Now | 17.07% | JP Morgan | Eric Joseph43% | $30 → $43 | Maintains | Overweight | Get Alert |
| 11/05/2024 | Buy Now | 49.74% | HC Wainwright & Co. | Edward White46% | $49 → $55 | Maintains | Buy | Get Alert |
| 11/05/2024 | Buy Now | -40.1% | Goldman Sachs | Corinne Jenkins47% | $20 → $22 | Maintains | Neutral | Get Alert |
| 10/29/2024 | Buy Now | 36.13% | TD Cowen | Tara Bancroft65% | → $50 | Initiates | → Buy | Get Alert |
| 09/18/2024 | Buy Now | 33.41% | HC Wainwright & Co. | Edward White46% | $49 → $49 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2024 | Buy Now | -7.43% | B. Riley Securities | Mayank Mamtani72% | $29 → $34 | Maintains | Buy | Get Alert |
| 08/07/2024 | Buy Now | -45.55% | Goldman Sachs | Corinne Jenkins47% | $18 → $20 | Maintains | Neutral | Get Alert |
| 08/06/2024 | Buy Now | 33.41% | HC Wainwright & Co. | Edward White46% | $49 → $49 | Reiterates | Buy → Buy | Get Alert |
| 05/02/2024 | Buy Now | 33.41% | HC Wainwright & Co. | Edward White46% | $45 → $49 | Maintains | Buy | Get Alert |
| 05/02/2024 | Buy Now | 8.9% | Ladenburg Thalmann | Matthew Kaplan65% | $39 → $40 | Maintains | Buy | Get Alert |
| 04/18/2024 | Buy Now | 22.52% | HC Wainwright & Co. | Edward White46% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2024 | Buy Now | -31.94% | JP Morgan | Eric Joseph43% | → $25 | Reiterates | Overweight → Overweight | Get Alert |
| 04/18/2024 | Buy Now | 6.18% | Ladenburg Thalmann | Matthew Kaplan65% | → $39 | Reiterates | Buy → Buy | Get Alert |
| 03/01/2024 | Buy Now | 22.52% | HC Wainwright & Co. | Edward White46% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 02/29/2024 | Buy Now | -64.61% | Goldman Sachs | Corinne Jenkins47% | $12 → $13 | Maintains | Neutral | Get Alert |
| 02/28/2024 | Buy Now | 22.52% | HC Wainwright & Co. | Edward White46% | $45 → $45 | Reiterates | Buy → Buy | Get Alert |
| 02/05/2024 | Buy Now | -21.05% | B. Riley Securities | Mayank Mamtani72% | $24 → $29 | Maintains | Buy | Get Alert |
| 01/11/2024 | Buy Now | 22.52% | HC Wainwright & Co. | Edward White46% | $41 → $45 | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | — | Jefferies | Matthew Andrews75% | — | Maintains | Buy | Get Alert |
| 11/01/2023 | Buy Now | -37.38% | JP Morgan | Eric Joseph43% | $22 → $23 | Maintains | Overweight | Get Alert |
| 10/20/2023 | Buy Now | -34.66% | B. Riley Securities | Mayank Mamtani72% | $32 → $24 | Maintains | Buy | Get Alert |
| 09/18/2023 | Buy Now | 11.63% | HC Wainwright & Co. | Edward White46% | → $41 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | -40.1% | JP Morgan | Eric Joseph43% | $34 → $22 | Maintains | Overweight | Get Alert |
| 08/03/2023 | Buy Now | -67.33% | Goldman Sachs | Corinne Jenkins47% | $16 → $12 | Maintains | Neutral | Get Alert |
| 08/02/2023 | Buy Now | -12.88% | B. Riley Securities | Mayank Mamtani72% | $42 → $32 | Maintains | Buy | Get Alert |
| 08/02/2023 | Buy Now | -67.33% | Goldman Sachs | Corinne Jenkins47% | $16 → $12 | Upgrade | Sell → Neutral | Get Alert |
| 08/01/2023 | Buy Now | -12.88% | B. Riley Securities | Mayank Mamtani72% | $42 → $32 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | 11.63% | HC Wainwright & Co. | Edward White46% | $34 → $41 | Maintains | Buy | Get Alert |
| 07/25/2023 | Buy Now | -56.44% | Goldman Sachs | Corinne Jenkins47% | $10 → $16 | Maintains | Sell | Get Alert |
| 07/24/2023 | Buy Now | -56.44% | Goldman Sachs | Corinne Jenkins47% | $10 → $16 | Maintains | Sell | Get Alert |
| 07/13/2023 | Buy Now | 14.35% | B. Riley Securities | Mayank Mamtani72% | → $42 | Reiterates | Buy → Buy | Get Alert |
| 06/01/2023 | Buy Now | -7.43% | HC Wainwright & Co. | Edward White46% | → $34 | Reiterates | → Buy | Get Alert |
| 05/31/2023 | Buy Now | -7.43% | HC Wainwright & Co. | Edward White46% | → $34 | Reiterates | → Buy | Get Alert |
| 05/02/2023 | Buy Now | 2.1% | Ladenburg Thalmann | Matthew Kaplan65% | $26 → $37.5 | Maintains | Buy | Get Alert |
| 05/01/2023 | Buy Now | -7.43% | HC Wainwright & Co. | Edward White46% | $28 → $34 | Reiterates | → Buy | Get Alert |
| 04/17/2023 | Buy Now | -34.66% | Cantor Fitzgerald | Prakhar Agrawal46% | → $24 | Reiterates | → Overweight | Get Alert |
| 04/14/2023 | Buy Now | -23.77% | HC Wainwright & Co. | Edward White46% | $24 → $28 | Reiterates | → Buy | Get Alert |
| 03/31/2023 | Buy Now | -34.66% | HC Wainwright & Co. | Edward White46% | → $24 | Reiterates | → Buy | Get Alert |
| 03/01/2023 | Buy Now | -34.66% | HC Wainwright & Co. | Edward White46% | → $24 | Reiterates | → Buy | Get Alert |
| 02/07/2023 | Buy Now | -34.66% | Cantor Fitzgerald | Prakhar Agrawal46% | $18 → $24 | Maintains | Overweight | Get Alert |
| 01/24/2023 | Buy Now | -31.94% | Evercore ISI Group | Joshua Schimmer45% | $16 → $25 | Maintains | Outperform | Get Alert |
| 12/30/2022 | Buy Now | -56.44% | Evercore ISI Group | Joshua Schimmer45% | $11 → $16 | Maintains | Outperform | Get Alert |
| 12/30/2022 | Buy Now | -83.66% | Goldman Sachs | Corinne Jenkins47% | $4 → $6 | Maintains | Sell | Get Alert |
| 12/30/2022 | Buy Now | -37.38% | B. Riley Securities | Mayank Mamtani72% | $17 → $23 | Maintains | Buy | Get Alert |
| 12/29/2022 | Buy Now | -83.66% | B of A Securities | Alec Stranahan32% | $5 → $6 | Maintains | Underperform | Get Alert |
| 12/29/2022 | Buy Now | -34.66% | HC Wainwright & Co. | Edward White46% | $19 → $24 | Maintains | Buy | Get Alert |
FAQ
What is the target price for TG Therapeutics (TGTX) stock?
The latest price target for TG Therapeutics (NASDAQ:TGTX) was reported by HC Wainwright & Co. on March 4, 2025. The analyst firm set a price target for $55.00 expecting TGTX to rise to within 12 months (a possible 49.74% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for TG Therapeutics (TGTX)?
The latest analyst rating for TG Therapeutics (NASDAQ:TGTX) was provided by HC Wainwright & Co., and TG Therapeutics reiterated their buy rating.
When was the last upgrade for TG Therapeutics (TGTX)?
The last upgrade for TG Therapeutics Inc happened on August 2, 2023 when Goldman Sachs raised their price target to $12. Goldman Sachs previously had a sell for TG Therapeutics Inc.
When was the last downgrade for TG Therapeutics (TGTX)?
There is no last downgrade for TG Therapeutics.
When is the next analyst rating going to be posted or updated for TG Therapeutics (TGTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of TG Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for TG Therapeutics was filed on March 4, 2025 so you should expect the next rating to be made available sometime around March 4, 2026.
Is the Analyst Rating TG Therapeutics (TGTX) correct?
While ratings are subjective and will change, the latest TG Therapeutics (TGTX) rating was a reiterated with a price target of $55.00 to $55.00. The current price TG Therapeutics (TGTX) is trading at is $36.73, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
